Rediff Logo
 Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Wedding | Women
Partner Channels: Bill Pay | Health | IT Education | Jobs | Technology | Travel
Line
Home > Money > Reuters > Report
May 29, 2001 		Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      

 
Reuters
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Novartis sets diabetes drug deal with Dr Reddy's

Novartis AG has agreed to license an anti-diabetes agent from Dr Reddy's Laboratories Ltd in return for up to $55 million in upfront and milestone payments plus royalties, Novartis said on Tuesday in Basle, Switzerland.

The agreement, which is subject to US regulatory clearance, gives the Swiss health care group exclusive worldwide rights to develop and commercialise insulin sensitizer DRF 4158. Dr Reddy's will have co-promotion rights in India. DRF 4158 aims to treat type 2 diabetes, diabetic dyslipidema, high blood pressure and obesity.

It is now in pre-clinical evaluation before it starts trials in humans.

Novartis head of development Joerg Reinhardt said in a statement the drug was an important addition to Novartis's pre-clinical pipeline in the field of metabolic diseases and would strengthen its portfolio of drugs for diabetes by adding an insulin sensitising compound.

Back to top
(c) Copyright 2000 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Tell us what you think of this report